NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA
    Nanobiotix spinoff Curadigm validates novel nanoprimer technology in RNA therapeutics
    Nanobiotix secures €10M in non-dilutive financing

    ALL NANOBIOTIX PRESS RELEASES

    Events

    September 18-22

    ESMO 2020

    More info
    September 23-25

    ImmunoRad 2020

    More info

    JOIN US


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer
     

    Download our latest
    Corporate Presentation

     
    English